leadf
logo-loader
viewOrthocell Ltd

Orthocell publishes positive pre-clinical trial study for CelGro nerve repair

Orthocell Ltd (ASX:OCC) managing director Paul Anderson updates Proactive Investors on the company’s positive pre-clinical study results for CelGro nerve regenerative treatment.

The results validate claims that the technique can deliver higher quality nerve repair, compared to existing methods.

Results also showed the use of CelGro in rats restored nerve fibres to complete regeneration, with these being indistinguishable from normal nerve histology.

Quick facts: Orthocell Ltd

Price: 0.34 AUD

ASX:OCC
Market: ASX
Market Cap: $62.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell 'in exciting regulatory phase' as it looks to drive its...

Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the...

on 22/9/20

2 min read